Akero Therapeutics, Inc. (NasdaqGM: AKRO)
Health Care · Biotechnology · US
$—
— today · — 1Y
Akero Therapeutics, Inc. (NasdaqGM: AKRO) operates in the Biotechnology industry within the Health Care sector.
trading between 41.77 and 54.83.
Tweenvest scores Akero Therapeutics, Inc. across four factors: quality 33/100. Its strongest factor is quality.
AKRO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.74
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $54.83
- 52-week low
- $41.77
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 69
- Next earnings
- —
About Akero Therapeutics, Inc.
Akero Therapeutics, Inc. is a biopharmaceutical firm dedicated to addressing cardio-metabolic disorders, with a specific focus on nonalcoholic steatohepatitis (NASH). Its primary objective is the creation of therapeutic agents aimed at re-establishing metabolic equilibrium and enhancing overall well-being. The company's flagship investigational drug is efruxifermin (EFX), a synthetic analog of fibroblast growth factor 21. EFX is designed to shield cells from stress and modulate the systemic metabolism of fats, carbohydrates, and proteins throughout the body. This promising compound is currently undergoing evaluation in a Phase 2a clinical investigation, known as the BALANCED study, for individuals diagnosed with biopsy-confirmed NASH. Originally established as Pippin Pharmaceuticals, Inc., the organization rebranded as Akero Therapeutics, Inc. in May 2018. Founded in 2017, Akero Therapeutics maintains its corporate headquarters in South San Francisco, California.
- Founded
- 2017
- Listed since
- Jun 20, 2019
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.